Levosimendan Kalceks

Levosimendan, the active ingredient in Levosimendan Kalceks, is a calcium sensitizer presented as an intravenous solution for intravenous use. It is employed in the management of acute decompensated heart failure to improve cardiac contractility and reduce vascular resistance in adult patients.

GNH USA supplies Levosimendan Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The company ensures consistent product availability and supports clinical procurement through dedicated logistics.

Levosimendan is used in the treatment of acute decompensated heart failure, a condition characterized by sudden worsening of cardiac function.

- Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. - Severe low‑output syndrome after cardiac surgery: provides hemodynamic support when conventional therapy is insufficient. - Chronic heart failure with reduced ejection fraction (adjunctive): may enhance contractility as part of a comprehensive management plan.

Levosimendan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: drop in blood pressure during infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate. - Flushing: transient warmth and redness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Allergic reactions: rash, pruritus, or anaphylaxis. - Pulmonary edema: worsening respiratory status. - Liver enzyme elevation: indicative of hepatic stress.

Levosimendan requires careful clinical monitoring and consideration of patient‑specific factors.

- Renal impairment: assess renal function and adjust infusion parameters as needed. - Hepatic impairment: monitor liver enzymes before and during therapy. - Hypotension: measure blood pressure frequently; be prepared to reduce infusion rate. - Concurrent vasodilators: avoid additive blood‑pressure lowering effects. - Pregnancy: safety not established; use only if potential benefit justifies risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilation may cause profound hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase levosimendan plasma levels. - Phosphodiesterase‑3 inhibitors (e.g., milrinone): heightened risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and volume status. - ACE inhibitors or ARBs: watch for excessive blood‑pressure reduction. - Digoxin: observe for arrhythmias, especially in patients with electrolyte disturbances.